Skip to main content

Advertisement

SpringerLink
Log in

Lamivudine and fingolimod co-administration in two patients with multiple sclerosis and occult hepatitis B virus infection

  • Letter to the Editor
  • Published:
Neurological Sciences Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Kappos L, Radue EW, O’Connor P et al (2010) A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 362:387–401

    Article  CAS  PubMed  Google Scholar 

  2. European Association for the Study of the Liver (2012) EASL Clinical Practice Guidelines: management of chronic hepatitis B virus infection. J Hepatol 57:167–185

    Article  Google Scholar 

  3. Penna A, Artini M, Cavalli A, Levrero M, Bertoletti A, Pilli M, Chisari FV, Rehermann B, Del Prete G, Fiaccadori F et al (1996) Long-lasting memory T cell responses following self-limited acute hepatitis B. J Clin Invest 98:1185–1194

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Song Z-Y, Yamasaki R, Kawano Y, Sato S, Masaki K, Yoshimura S et al (2015) Peripheral blood T cell dynamics predict relapse in multiple sclerosis patients on Fingolimod. PLoS One 10:e0124923

    Article  PubMed  PubMed Central  Google Scholar 

  5. Raimondo G, FIlomia R, Pollicino T (2013) Occult HBV infection. Semin Immunopathol 35:39–52

    Article  CAS  PubMed  Google Scholar 

  6. López-Serrano P, de la Fuente Briongos E, Carrera Alonso E, Lázaro Pérez-Calle J, Fernández Rodríguez C (2015) Hepatitis B and immunosuppressive therapies for chronic inflammatory disease: when and how to apply prophylaxis, with a special focus on corticosteroid therapy. World J Hepatol 7:539–547

Download references

Acknowledgments

This study did not receive specific funding.

Author information

Authors and Affiliations

  1. Department of Neurosciences, Reproductive and Odontostomatological Sciences, University Federico II, Via Pansini, 5, 80131, Naples, Italy

    Francesco Saccà, Chiara Pane, Anna De Rosa & Vincenzo Brescia Morra

  2. Department of Translational Medical Sciences, University Federico II, Naples, Italy

    Margherita Matarazzo

Authors
  1. Francesco Saccà
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chiara Pane
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anna De Rosa
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Margherita Matarazzo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Vincenzo Brescia Morra
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Francesco Saccà.

Ethics declarations

Conflict of interest

F. Saccà received personal compensation from Novartis, Almirall, Genzyme, and TEVA for public speaking, editorial work and advisory boards. C. Pane reports no disclosures. A. de Rosa reports no disclosures. M. Matarazzo reports no disclosures. V. B. Morra received compensation for public speaking, and advisory boards from Biogen, Merk Serono, Bayer, Genzyme, Almirall, Novartis, and TEVA.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Saccà, F., Pane, C., De Rosa, A. et al. Lamivudine and fingolimod co-administration in two patients with multiple sclerosis and occult hepatitis B virus infection. Neurol Sci 38, 501–502 (2017). https://doi.org/10.1007/s10072-016-2726-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10072-016-2726-3

Keywords

Search

Navigation